Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology have moved closer to developing a drug-eluting contact lens designed for prolonged delivery of latanoprost, commonly used to treat glaucoma. Using FDA-approved materials, the researchers created the CLs by encapsulating latanoprost-polymer films in hydrogel. Their findings are described online and will be in the January 2014 printed issue of Biomaterials. Read the NIH abstract. Read a PDF version of the study at Science Direct.
Only a day ago, researchers announced that they had mapped the molecular underpinnings of glaucoma. Read the blog post.
No comments:
Post a Comment